The Managers of GreyBird Ventures Partner with JF Healthcare in China

China, the world’s second largest and fastest growing market for healthcare products and services, cannot be ignored in the plans for any medical technology enterprise. It is a country where doing business as a foreign entity can be both highly complex and fraught with potential pitfalls. Therefore, the managers of GreyBird Ventures have decided to partner with a trusted enterprise, JiuFeng Healthcare (JF), to provide advice, assistance, and access to the Chinese market both for our firm and our portfolio companies. The GreyBird Managers have enjoyed a decades-long trustful relationship with the Founder, Chairman, and CEO of JF, Frank Wu...

Hummingbird Diagnostics GmbH and Saarland University Collaborate in Early Disease Detection Based on Molecular Markers: miRNA Experts Sign Framework Agreement

HEIDELBERG and SAARBRÜCKEN, November 14, 2017 – Hummingbird Diagnostics GmbH, specialized in early disease detection using molecular markers derived from blood, and Saarland University agreed on a comprehensive framework agreement regarding an expanded collaboration in the field of molecular diagnostics. The work aims at the validation of miRNA biomarkers in blood samples, allowing for an early detection of common serious diseases including lung cancer, chronic obstructive lung disease (COPD), Alzheimer’s and Parkinson’s. The project partners at Saarland University are the Department of Human Genetics and the Chair of Clinical Bioinformatics. Hummingbird Diagnostics has been maintaining long-standing research collaborations with both...

Tasso, Ceres Nanosciences, George Mason University, and the United States Army Medical Research Institute of Infectious Diseases receive $4.25M to develop a universal surveillance platform for infectious disease outbreaks.

MANASSAS, Va. — September 28, 2017 — Tasso, Inc. (Tasso), Ceres Nanosciences (Ceres), George Mason University (Mason), and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) today announced the commencement of a $11.7 million program, funded by the Defense Threat Reduction Agency (DTRA), to develop a reliable, safe, and simple universal surveillance platform for infectious disease outbreaks. During this multi-year program, which will be initiated with $4.25 million in funding from DTRA, Ceres will integrate its Nanotrap® particle technology, which can capture, concentrate, and preserve pathogens and other biomolecules, into Tasso’s HemoLink™ device for simple and painless collection...

Ceres Nanosciences and Innatoss Laboratories to Launch the Nanotrap® Lyme Antigen Test in the European Union

The Nanotrap® Lyme Antigen Test, a direct urine test for the presence of a Lyme bacteria protein, will be made available to patients throughout Europe. Ceres Nanosciences, Inc. (Ceres) and Innatoss Laboratories (Innatoss) announced today a partnership that will deliver the Nanotrap® Lyme Antigen Test out of Innatoss’ clinical testing laboratories in the Netherlands for patient benefit throughout the European Union. The Nanotrap® Lyme Antigen Test is the first highly-sensitive, urine-based test capable of directly detecting a Lyme protein antigen in a patient at any stage of infection. In 2015, Ceres launched the Nanotrap® Lyme Antigen Test for patients across...

Ceres Receives $750K DOD Award

Ceres receives $750K award from US Department of Defense to adapt Nanotrap® Platform to Zika and emerging febrile illness pathogens from non-invasive sample types. Ceres Nanosciences, Inc. (Ceres) today announced the commencement of a development program, funded by the Defense Advanced Research Projects Agency (DARPA) of the US Department of Defense, to use Ceres’ Nanotrap® particle technology to commercialize sample processing tools for improved detection of Zika and other emerging pathogens from non-invasively collected urine and saliva specimens. During the 12-month performance of this program, Ceres will work in collaboration with George Mason University (GMU) to adapt the Nanotrap® platform...

Ceres Opens $9 Million Series A Round

Ceres Nanosciences opens $9 Million Series A round with $3 Million investment from GreyBird Ventures for the development of novel diagnostics powered by its Nanotrap® Platform. Ceres Nanosciences, Inc. today announced the completion of a $3MM Million Series A financing as part of a larger, $9MM Series A round. GreyBird Ventures, an early stage venture fund, with offices in Boston, is leading the round. GreyBird is committing up to $5.5MM over the next year, and is supporting Ceres in completing the round with additional investment from strategic industry partners. The Nanotrap technology was invented at George Mason University and developed...

GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.


For additional information, please contact: